Pembrolizumab plus axitinib: a new treatment option for patients with metastatic renal cell carcinoma

Chin Clin Oncol. 2019 Oct;8(S1):S21. doi: 10.21037/cco.2019.04.05. Epub 2019 May 10.
No abstract available

Publication types

  • Editorial

MeSH terms

  • Antibodies, Monoclonal, Humanized / pharmacology
  • Antibodies, Monoclonal, Humanized / therapeutic use*
  • Antineoplastic Agents / pharmacology
  • Antineoplastic Agents / therapeutic use*
  • Axitinib / pharmacology
  • Axitinib / therapeutic use*
  • Carcinoma, Renal Cell / drug therapy*
  • Carcinoma, Renal Cell / pathology
  • Female
  • Humans
  • Male
  • Neoplasm Metastasis

Substances

  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents
  • Axitinib
  • pembrolizumab